ANDA "Major/Minor" Amendment Reclassification Proposed By FDA
This article was originally published in The Tan Sheet
FDA's Office of Generic Drugs may change its classification of ANDA amendments to allow the vast majority to be treated as "minor" amendments receiving 60-day reviews.
You may also be interested in...
FDA is developing a process to flag NDAs that may pose difficulties for future generic development, Commissioner Mark McClellan, MD/PhD, said at the Generic Pharmaceutical Association annual meeting in Rio Grande, Puerto Rico Jan. 29
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands